PTPN22 variant R620W is associated with reduced toll-like receptor 7-induced type i interferon in systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 67, Issue 9, 2015, Pages 2403-2414

  Wang, Yaya ^a   Ewart, David ^a   Crabtree, Juliet N ^a   Yamamoto, Ami ^a   Baechler, Emily C ^a   Fazeli, Parastoo ^a   Peterson, Erik J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BELIMUMAB; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PREDNISONE; RESIQUIMOD; STAT1 PROTEIN; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR; IMIDAZOLE DERIVATIVE; INTERFERON; MEMBRANE PROTEIN; PTPN22 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; TLR7 PROTEIN, HUMAN; TLR7 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY SCORE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE ACTIVATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SLEDAI; SUBSTITUTION REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENIC MOUSE; UPREGULATION; AGONISTS; ANIMAL; CASE CONTROL STUDY; DENDRITIC CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANIMALS; CASE-CONTROL STUDIES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; INTERFERON TYPE I; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE GLYCOPROTEINS; MICE, TRANSGENIC; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; STAT1 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940108777     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39211     Document Type: Article

References (56)

1. Crow MK., Type I interferon in the pathogenesis of lupus. J Immunol 2014; 192: 5459-68.
2. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-5.
3. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23.
4. Gonzalez-Navajas JM, Lee J, David M, Raz E., Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12: 125-35.
5. Swiecki M, Colonna M., Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010; 234: 142-62.
6. Celhar T, Magalhaes R, Fairhurst AM., TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res 2012; 53: 58-77.
7. Sisirak V, Ganguly D, Lewis KL, Couillault C, Tanaka L, Bolland S, et al., Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. J Exp Med 2014; 211: 1969-76.
8. Rowland SL, Riggs JM, Gilfillan S, Bugatti M, Vermi W, Kolbeck R, et al., Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med 2014; 211: 1977-91.
9. Dai C, Deng Y, Quinlan A, Gaskin F, Tsao BP, Fu SM., Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol 2014; 31C: 87-96.
10. Stanford SM, Bottini N., PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 2014; 10: 602-11.
11. Chang HH, Tseng W, Cui J, Costenbader K, Ho IC., Altered expression of protein tyrosine phosphatase, non-receptor type 22 isoforms in systemic lupus erythematosus. Arthritis Res Ther 2014; 16: R14.
12. Moez P, Soliman E., Association of PTPN22 gene polymorphism and systemic lupus erythematosus in a cohort of Egyptian patients: impact on clinical and laboratory results. Rheumatol Int 2012; 32: 2753-8.
13. Reddy MV, Johansson M, Sturfelt G, Jonsen A, Gunnarsson I, Svenungsson E, et al., The R620W C/T polymorphism of the gene PTPN22 is associated with SLE independently of the association of PDCD1. Genes Immun 2005; 6: 658-62.
14. Namjou B, Kim-Howard X, Sun C, Adler A, Chung SA, Kaufman KM, et al., PTPN22 association in systemic lupus erythematosus (SLE) with respect to individual ancestry and clinical sub-phenotypes. PLoS One 2013; 8: e69404.
15. Ostanek L, Ostanek-Panka M, Bobrowska-Snarska D, Binczak-Kuleta A, Fischer K, Kaczmarczyk M, et al., PTPN22 1858C>T gene polymorphism in patients with SLE: association with serological and clinical results. Mol Biol Rep 2014; 41: 6195-200.
16. Bottini N, Peterson EJ., Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. Annu Rev Immunol 2014; 32: 83-119.
17. Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, et al., A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest 2013; 123: 2024-36.
18. Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, Mikulski Z, et al., The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity 2013; 39: 111-22.
19. Chang HH, Miaw SC, Tseng W, Sun YW, Liu CC, Tsao HW, et al., PTPN22 modulates macrophage polarization and susceptibility to dextran sulfate sodium-induces colitis. J Immunol 2013; 191: 2134-43.
20. Hacker H, Tseng PH, Karin M., Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 2011; 11: 457-68.
21. Maine CJ, Marquardt K, Scatizzi JC, Pollard KM, Kono DH, Sherman LA., The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus. Clin Immunol 2015; 156: 65-73.
22. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
24. Menard L, Saadoun D, Isnardi I, Ng YS, Meyers G, Massad C, et al., The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 2011; 121: 3635-44.
25. Kariuki SN, Crow MK, Niewold TB., The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-α activity and low tumor necrosis factor α levels in patients with lupus. Arthritis Rheum 2008; 58: 2818-23.
26. Shrivastav M, Niewold TB., Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol 2013; 4: 319.
27. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al., Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
28. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al., Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3: 499.
29. Stetson DB, Medzhitov R., Type I interferons in host defense. Immunity 2006; 25: 373-81.
30. Barrat FJ, Coffman RL., Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008; 223: 271-83.
31. Ida JA, Shrestha N, Desai S, Pahwa S, Hanekom WA, Haslett PA., A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J Immunol Methods 2006; 310: 86-99.
32. Asselin-Paturel C, Trinchieri G., Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 2005; 202: 461-5.
33. Reizis B, Colonna M, Trinchieri G, Barrat F, Gilliet M., Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? Nat Rev Immunol 2011; 11: 558-65.
34. James JA, Robertson JM., Lupus and Epstein-Barr. Curr Opin Rheumatol 2012; 24: 383-8.
35. Francis L, Perl A., Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumtol 2010; 5: 59-74.
36. Quan TE, Roman RM, Rudenga BJ, Holers VM, Craft JE., Epstein-Barr virus promotes interferon-α production by plasmacytoid dendritic cells. Arthritis Rheum 2010; 62: 1693-701.
37. Boechat AL, Ogusku MM, Sadahiro A, Dos Santos MC., Association between the PTPN22 1858C/T gene polymorphism and tuberculosis resistance. Infect Genet Evol 2013; 16: 310-3.
38. Nahum A, Bates A, Sharfe N, Roifman CM., Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 122: 1220-2.
39. Azarian M, Busson M, Rocha V, Ribaud P, Peffault de Latour R, Bleux H, et al., The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations. Transplantation 2008; 85: 1859-62.
40. Chapman SJ, Khor CC, Vannberg FO, Maskell NA, Davies CW, Hedley EL, et al., PTPN22 and invasive bacterial disease. Nat Genet 2006; 38: 499-500.
41. Fousteri G, Jofra T, Di Fonte R, Kuka M, Iannacone M, Battaglia M., PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner. Clin Immunol 2015; 156: 98-108.
42. Montes-Cano MA, Garcia-Lozano JR, Aguilar-Reina J, Romero-Gomez M, Barroso N, Nunez- Roldan A, et al., PTPN22 C1858T polymorphism and the outcome of hepatitis C virus infection. Viral Immunol 2008; 21: 491-4.
43. Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, Meng X, et al., The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011; 43: 902-7.
44. Cervantes-Barragan L, Lewis KL, Firner S, Thiel V, Hugues S, Reith W, et al., Plasmacytoid dendritic cells control T-cell response to chronic viral infection. Proc Natl Acad Sci USA 2012; 109: 3012-7.
45. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E., Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005; 115: 695-702.
46. Sobel DO, Goyal D, Ahvazi B, Yoon JW, Chung YH, Bagg A, et al., Low dose poly I:C prevents diabetes in the diabetes prone BB rat. J Autoimmun 1998; 11: 343-52.
47. Yarilina A, DiCarlo E, Ivashkiv LB., Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol 2007; 178: 2204-11.
48. Sweeney SE, Corr M, Kimbler TB., Role of interferon regulatory factor 7 in serum-transfer arthritis: regulation of interferon-β production. Arthritis Rheum 2012; 64: 1046-56.
49. Sauer I, Schaljo B, Vogl C, Gattermeier I, Kolbe T, Muller M, et al., Interferons limit inflammatory responses by induction of tristetraprolin. Blood 2006; 107: 4790-7.
50. Reboldi A, Dang EV, McDonald JG, Liang G, Russell DW, Cyster JG., 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 2014; 345: 679-84.
51. Postal M, Appenzeller S., The role of tumor necrosis factor-α (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011; 56: 537-43.
52. Aringer M, Smolen JS., Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004; 13: 344-7.
53. Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, et al., Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease. Arthritis Res Ther 2013; 15: R39.
54. Wang J, Shao Y, Bennett TA, Shankar RA, Wightman PD, Reddy LG., The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J Biol Chem 2006; 281: 37427-34.
55. Desnues B, Macedo AB, Roussel-Queval A, Bonnardel J, Henri S, Demaria O, et al., TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci U S A 2014; 111: 1497-502.
56. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al., Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-7.